gliclazide has been researched along with Diabetes Mellitus in 79 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gliclazide is a 'second generation' oral hypoglycaemic agent." | 7.75 | Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. ( Avery, GS; Brogden, RN; Heel, RC; Holmes, B; Speight, TM, 1984) |
| "We describe one patient with diabetes mellitus treated by fenofibrate monotherapy since several years; 48 h after gliclazide therapy was introduced, rhabdomyolysis occurred." | 7.73 | [Rhabdomyolysis induced by fenofibrate monotherapy]. ( Amaniou, M; Archambeaud-Mouveroux, F; Combes, C; Galinat, S; Lassandre, S; Lopez, S; Teissier, MP, 2006) |
| "The effects of gliclazide on blood sugar levels and the micro-vascular system have been specified by the latest international studies of this antidiabetic agent presented at the 11th World Congress on Diabetes Mellitus." | 6.15 | [Hypoglycemic and microvascular properties of gliclazide: a review of the latest international studies]. ( Lesobre, B, 1983) |
| "Gliclazide is a widely used sulfonylurea hypoglycemic drug, but its cancer risk remains controversial." | 5.51 | Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis. ( Chen, H; Gong, J; Sun, J; Wang, M; Wen, W; Wu, P; Zhao, M, 2019) |
| "Gliclazide is a 'second generation' oral hypoglycaemic agent." | 3.75 | Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. ( Avery, GS; Brogden, RN; Heel, RC; Holmes, B; Speight, TM, 1984) |
| "We describe one patient with diabetes mellitus treated by fenofibrate monotherapy since several years; 48 h after gliclazide therapy was introduced, rhabdomyolysis occurred." | 3.73 | [Rhabdomyolysis induced by fenofibrate monotherapy]. ( Amaniou, M; Archambeaud-Mouveroux, F; Combes, C; Galinat, S; Lassandre, S; Lopez, S; Teissier, MP, 2006) |
| "We evaluated insulin resistance and assessed the effect of gliclazide on insulin resistance in a patient with diabetes mellitus associated with Turner's syndrome." | 3.69 | Insulin resistance in a patient with diabetes mellitus associated with Turner's syndrome. ( Hashimoto, K; Hisatake, K; Kumon, Y; Suehiro, T; Sumiyoshi, R, 1994) |
| "The clinical efficacy of gliclazide and its effect on plasma glucose, body weight and serum lipids was assessed in a 3 months open trial of 30 obese, Non-Insulin Dependent diabetes mellitus (NIDDM) patients who failed to respond to diet therapy alone." | 3.68 | Gliclazide in the treatment of obese non-insulin dependent diabetic patients. ( Seshiah, V; Suresh, K; Venkataraman, S, 1993) |
| "Gliclazide is an oral hypoglycaemic agent which has been shown in animal models to reduce platelet adhesiveness." | 2.64 | Effect on platelet adhesiveness in diabetics after long-term treatment with a new oral hypoglycaemic agent, gliclazide. ( Coce, F; Maitre, D; Mustovic, D; Rubinjoni, Z; Skrabalo, Z; Turk, Z, 1978) |
| "Treatment with glyburide significantly reduced aggregation in response to 10 microM of epinephrine and collagen at 750 microgram/ml." | 2.36 | Sulfonylureas and platelet function. ( Jackson, WP; Jacobs, P; Kernoff, L; Klaff, LJ; Vinik, AI, 1981) |
| " The optimized formulation based on in vitro data was selected for a bioavailability study in rabbits." | 1.72 | Development, in vitro Evaluation, and in vivo Study of Adhesive Buccal Films for the Treatment of Diabetic Pediatrics via Trans Mucosal Delivery of Gliclazide. ( Adogim, SS; Albilaihi, HM; Alburaykan, AI; Aldohan, NS; Alharbi, RF; Aljohani, AR; Alruthea, LM; Gaber, DA, 2022) |
| " In vivo studies showed a twofold rise in bioavailability through SNEDDS with a significant decline in blood glucose levels compared to plain drug suspension suggesting a lipid-based system as an alternative approach for treating diabetes." | 1.51 | Quality by Design Approach for Developing Lipid-Based Nanoformulations of Gliclazide to Improve Oral Bioavailability and Anti-Diabetic Activity. ( Cheruvu, HS; Dodoala, S; Pailla, SR; Patel, P; Rangaraj, N; Sampathi, S, 2019) |
| "Gliclazide is a widely used sulfonylurea hypoglycemic drug, but its cancer risk remains controversial." | 1.51 | Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis. ( Chen, H; Gong, J; Sun, J; Wang, M; Wen, W; Wu, P; Zhao, M, 2019) |
| "Gliclazide microcapsules were prepared using sodium alginate and mucoadhesive polymer such as sodium carboxymethyl cellulose (sodium CMC), carbopol 934P or hydroxy propylmethyl cellulose (HPMC) by orifice-ionic gelation method." | 1.35 | Design and development of gliclazide mucoadhesive microcapsules: in vitro and in vivo evaluation. ( Anand, V; Prajapati, SK; Tripathi, P; Ubaidulla, U, 2008) |
| "The onset of Type 2 diabetes is insidious and is usually recognized only 5-12 years after hyperglycaemia develops." | 1.30 | Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection. ( Muggeo, M, 1998) |
| "Gliclazide was given to group A following CSII and to 5 obese NIDDM patients (group B) in their habitual hyperglycemic state." | 1.28 | Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia. ( Cerasi, E; del Rio, G; Della Casa, L; Glaser, B, 1991) |
| " The mean pharmacokinetic parameters of elimination rate (ke), time to reach the peak level (tmax), elimination half-life (t 1/2), and volume of distribution (Vd) were 0." | 1.27 | Pharmacokinetics of gliclazide in healthy and diabetic subjects. ( Hase, A; Kaneko, S; Kimura, M; Kobayashi, K; Matsuoka, A; Sakoguchi, T, 1984) |
| " Several pharmacokinetic parameters for the blood gliclazide were derived from the decay curves of the blood drug levels." | 1.26 | Influence of blood proteins on biomedical analysis. III. Pharmacokinetics and protein binding of gliclazide. ( Hata, M; Kimura, M; Kitani, Y; Kobayashi, K; Matsuoka, A; Sakoguchi, T, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (49.37) | 18.7374 |
| 1990's | 14 (17.72) | 18.2507 |
| 2000's | 14 (17.72) | 29.6817 |
| 2010's | 9 (11.39) | 24.3611 |
| 2020's | 3 (3.80) | 2.80 |
| Authors | Studies |
|---|---|
| Gaber, DA | 1 |
| Alburaykan, AI | 1 |
| Alruthea, LM | 1 |
| Aldohan, NS | 1 |
| Alharbi, RF | 1 |
| Aljohani, AR | 1 |
| Albilaihi, HM | 1 |
| Adogim, SS | 1 |
| Sekar, V | 1 |
| Mani, S | 1 |
| Malarvizhi, R | 1 |
| Barathidasan, R | 1 |
| Vasanthi, HR | 1 |
| Jahan, H | 1 |
| Choudhary, MI | 1 |
| Raslan, IA | 1 |
| McDonald, EG | 1 |
| Lee, TC | 1 |
| Cho, JH | 1 |
| Kang, E | 1 |
| Lee, BH | 1 |
| Kim, GH | 1 |
| Choi, JH | 1 |
| Yoo, HW | 1 |
| Srivastava, D | 1 |
| Fatima, Z | 1 |
| Kaur, CD | 1 |
| Cordiner, RLM | 1 |
| Pearson, ER | 2 |
| Patel, P | 1 |
| Pailla, SR | 1 |
| Rangaraj, N | 1 |
| Cheruvu, HS | 1 |
| Dodoala, S | 1 |
| Sampathi, S | 1 |
| Wen, W | 1 |
| Gong, J | 1 |
| Wu, P | 1 |
| Zhao, M | 1 |
| Wang, M | 1 |
| Chen, H | 1 |
| Sun, J | 1 |
| Zheng, M | 1 |
| Li, LZ | 1 |
| Jiang, ZA | 1 |
| Li, LH | 1 |
| Feng, YG | 1 |
| Fu, XH | 1 |
| Bazalová, Z | 1 |
| Rypácková, B | 1 |
| Broz, J | 1 |
| Brunerová, L | 1 |
| Polák, J | 1 |
| Rusavý, Z | 1 |
| Treslová, L | 1 |
| Andel, M | 1 |
| Spasov, AA | 1 |
| Kosolapov, VA | 1 |
| Chepliaeva, NI | 1 |
| Bahadori, B | 1 |
| Trinker, M | 1 |
| Wallner, SJ | 1 |
| Yazdani-Biuki, B | 1 |
| Wascher, TC | 1 |
| Patel, A | 1 |
| Chalmers, J | 1 |
| Chaturvedi, V | 1 |
| Currie, R | 1 |
| Monaghan, H | 1 |
| Neal, B | 1 |
| Starkey, BJ | 1 |
| Powell, RJ | 1 |
| Gribble, FM | 1 |
| Clark, PM | 1 |
| Hattersley, AT | 1 |
| Lawrence, JM | 1 |
| Reid, J | 1 |
| Taylor, GJ | 1 |
| Stirling, C | 1 |
| Reckless, JP | 1 |
| Okouchi, M | 1 |
| Okayama, N | 1 |
| Omi, H | 1 |
| Imaeda, K | 1 |
| Fukutomi, T | 1 |
| Nakamura, A | 1 |
| Itoh, M | 1 |
| Zhu, CR | 1 |
| Liu, ZH | 1 |
| Sun, KH | 1 |
| Ni, ZZ | 1 |
| Archambeaud-Mouveroux, F | 1 |
| Lopez, S | 1 |
| Combes, C | 1 |
| Lassandre, S | 1 |
| Amaniou, M | 1 |
| Teissier, MP | 1 |
| Galinat, S | 1 |
| Nagy, V | 1 |
| Pipili, C | 1 |
| Cholongitas, E | 1 |
| Prajapati, SK | 1 |
| Tripathi, P | 1 |
| Ubaidulla, U | 1 |
| Anand, V | 1 |
| Almér, LO | 1 |
| Lesobre, B | 1 |
| Holmes, B | 1 |
| Heel, RC | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Kobayashi, K | 5 |
| Kimura, M | 5 |
| Sakoguchi, T | 3 |
| Hase, A | 1 |
| Matsuoka, A | 5 |
| Kaneko, S | 3 |
| Pan, CY | 1 |
| Charles, BG | 1 |
| Ravenscroft, PJ | 1 |
| Bodansky, HJ | 1 |
| Medback, S | 1 |
| Cudworth, AG | 1 |
| Rees, LH | 1 |
| de Silva, RS | 1 |
| Brogard, JM | 1 |
| Pinget, M | 1 |
| Leconte, A | 1 |
| Dorner, M | 1 |
| Klaff, LJ | 2 |
| Kernoff, L | 2 |
| Vinik, AI | 3 |
| Jackson, WP | 3 |
| Jacobs, P | 3 |
| Paton, RC | 1 |
| Kernoff, PB | 1 |
| Wales, JK | 1 |
| McNicol, GP | 1 |
| Gastpar, H | 1 |
| Weissgerber, PW | 1 |
| Enzmann, F | 1 |
| Zoltobrocki, M | 1 |
| Wheeley, MS | 1 |
| Balabolkin, MI | 3 |
| Morozova, TP | 2 |
| Zhizhina, SA | 2 |
| Gavriliuk, LI | 1 |
| Novikova, NV | 1 |
| Nepsha, VD | 1 |
| Wajchenberg, BL | 1 |
| Nery, M | 1 |
| Leme, CE | 1 |
| Silveira, AA | 1 |
| Fioratti, P | 1 |
| Germek, OA | 1 |
| Berber, MJ | 1 |
| Tomkin, GH | 1 |
| Villiger, U | 1 |
| Djurić, DS | 1 |
| Djordjević, PB | 1 |
| Micić, D | 1 |
| Dragasević, M | 1 |
| Violi, F | 1 |
| De Mattia, GC | 1 |
| Alessandri, C | 1 |
| Perrone, A | 1 |
| Vezza, E | 1 |
| Golubiatnikova, GA | 1 |
| Koroleva, TV | 1 |
| Titova, GP | 1 |
| Kitani, Y | 1 |
| Hata, M | 3 |
| Bour, H | 1 |
| Kitamura, H | 1 |
| Kimura, Y | 2 |
| Takashima, S | 1 |
| Ino, T | 1 |
| Kumar, S | 1 |
| Keswani, P | 1 |
| Bose, BS | 1 |
| Agrawal, JK | 1 |
| Kumon, Y | 1 |
| Hisatake, K | 1 |
| Suehiro, T | 1 |
| Sumiyoshi, R | 1 |
| Hashimoto, K | 1 |
| Seshiah, V | 1 |
| Venkataraman, S | 1 |
| Suresh, K | 1 |
| Zbrońska, H | 1 |
| Grzeszczak, W | 1 |
| Jendryczko, A | 1 |
| Zbroński, R | 1 |
| Kuźniewicz, R | 1 |
| Taylor, AR | 1 |
| Brownsill, RD | 1 |
| Grandon, H | 1 |
| Lefoulon, F | 1 |
| Petit, A | 1 |
| Luijten, W | 1 |
| Kopelman, PG | 1 |
| Walther, B | 1 |
| Davis, TM | 1 |
| Parsons, RW | 1 |
| Broadhurst, RJ | 1 |
| Hobbs, MS | 1 |
| Jamrozik, K | 1 |
| Muggeo, M | 1 |
| Gougeon, R | 1 |
| Styhler, K | 1 |
| Morais, JA | 1 |
| Jones, PJ | 1 |
| Marliss, EB | 1 |
| Crepaldi, G | 1 |
| Fioretto, P | 1 |
| Abad, S | 1 |
| Moachon, L | 1 |
| Blanche, P | 1 |
| Bavoux, F | 1 |
| Sicard, D | 1 |
| Salmon-Céron, D | 1 |
| Bonnefont-Rousselot, D | 1 |
| Ponari, O | 1 |
| Civardi, E | 1 |
| Megha, S | 1 |
| Pini, M | 1 |
| Portioli, D | 1 |
| Dettori, AG | 1 |
| Malan, E | 1 |
| King, JB | 1 |
| Kalk, WJ | 1 |
| Bracher, M | 1 |
| Charbonnel, B | 1 |
| Estivals, JP | 1 |
| Giraudet, MC | 1 |
| Videau, JY | 1 |
| Rubinjoni, Z | 1 |
| Turk, Z | 1 |
| Coce, F | 1 |
| Mustovic, D | 1 |
| Maitre, D | 1 |
| Skrabalo, Z | 1 |
| Parodi, FA | 1 |
| Sankalé, M | 1 |
| Signate, S | 1 |
| Sow, AM | 1 |
| Soumah, A | 1 |
| Forette, B | 1 |
| Polosa, P | 1 |
| Mughini, L | 1 |
| Bernasconi, D | 1 |
| Mazzi, C | 1 |
| Montenero, P | 1 |
| Leotta, S | 1 |
| De Vigan, C | 1 |
| Delporte, MP | 1 |
| Thomas, M | 1 |
| Perrault, M | 1 |
| Brindley, DN | 1 |
| Gram, J | 1 |
| Jespersen, J | 1 |
| Igaki, A | 1 |
| Della Casa, L | 1 |
| del Rio, G | 1 |
| Glaser, B | 1 |
| Cerasi, E | 1 |
| Krall, LP | 1 |
| Doi, K | 1 |
| Ward, G | 1 |
| Harrison, LC | 1 |
| Proietto, J | 1 |
| Aitken, P | 1 |
| Nankervis, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes[NCT01238380] | 1,916 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for gliclazide and Diabetes Mellitus
| Article | Year |
|---|---|
Multicomponent Pharmaceutical Cocrystals: A Novel Approach for Combination Therapy.
Topics: Asthma; Chemistry, Pharmaceutical; Crystallization; Diabetes Mellitus; Drug Therapy, Combination; Fl | 2018 |
Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Rela | 2019 |
Diabetes and vascular disease: a new international trial.
Topics: Antihypertensive Agents; Developing Countries; Diabetes Complications; Diabetes Mellitus; Diabetic A | 2003 |
[Hypoglycemic and microvascular properties of gliclazide: a review of the latest international studies].
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Retinopathy; Female; Glic | 1983 |
Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
Topics: Absorption; Animals; Blood Glucose; Blood Platelets; Clinical Trials as Topic; Diabetes Mellitus; Di | 1984 |
Sulfonylureas and platelet function.
Topics: Adenosine Diphosphate; Blood Glucose; Blood Platelets; Collagen; Diabetes Mellitus; Diabetic Angiopa | 1981 |
Gliclazide modified release: its place in the therapeutic armamentarium.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Secretion; Islets | 2000 |
[Antioxidant and anti-AGE therapeutics: evaluation and perspectives].
Topics: Antioxidants; Chromans; Diabetes Mellitus; Gliclazide; Glycation End Products, Advanced; Guanidines; | 2001 |
Metabolic approach to atherosclerosis: effect of gliclazide.
Topics: Animals; Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Disease Models, Animal; Glicla | 1992 |
Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients.
Topics: Arteriosclerosis; Diabetes Mellitus; Diabetic Angiopathies; Fibrinolysis; Gliclazide; Humans | 1992 |
14 trials available for gliclazide and Diabetes Mellitus
| Article | Year |
|---|---|
Genetic cause of hyperglycaemia and response to treatment in diabetes.
Topics: Adult; Aged; ATP-Binding Cassette Transporters; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, | 2003 |
Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated | 2004 |
[Advanced credit: patient enrolling and therapy initiation in the ADVANCE trial].
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabete | 2007 |
[Hypoglycemic and microvascular properties of gliclazide: a review of the latest international studies].
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Retinopathy; Female; Glic | 1983 |
Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
Topics: Absorption; Animals; Blood Glucose; Blood Platelets; Clinical Trials as Topic; Diabetes Mellitus; Di | 1984 |
The effects of gliclazide in diabetes: a comparison with tolbutamide.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Gliclazide; Humans; Lipids; Sulfonylurea | 1982 |
[Clinical trial with a new oral antidiabetic, gliclazid, in general practice (author's transl)].
Topics: Acetone; Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Female; Gliclazide | 1982 |
Effects of the sulphonylurea drugs gliclazide and glibenclamide on blood glucose control and platelet function.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Female; Gliclazide; Glyburide; Humans; Male; Middle A | 1979 |
An evaluation of the effects of some sulphonylureas on platelet function.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Female; Gliclazide; Glipizide; Humans; L | 1977 |
[A new therapeutic approach to diabetes. Long-term survey].
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Retinopathy; Drug | 1977 |
[Survey of 832 case records of diabetes of adult onset treated by Diamicron. Evolution of metabolism and weight].
Topics: Adult; Aged; Biguanides; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Fe | 1978 |
Effect on platelet adhesiveness in diabetics after long-term treatment with a new oral hypoglycaemic agent, gliclazide.
Topics: Adult; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diet, Diabetic; Fema | 1978 |
[Long-term ambulatory treatment of diabetics with gliclazide].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Drug Tolerance; Female; G | 1979 |
Gliclazide (diamicron) in metabolic and vascular treatment of diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus; Female; Gliclazide; Humans; Male; Obesity; Sulfonylurea Compounds | 1977 |
57 other studies available for gliclazide and Diabetes Mellitus
| Article | Year |
|---|---|
Development, in vitro Evaluation, and in vivo Study of Adhesive Buccal Films for the Treatment of Diabetic Pediatrics via Trans Mucosal Delivery of Gliclazide.
Topics: Adhesives; Animals; Child; Diabetes Mellitus; Gliclazide; Humans; Hypromellose Derivatives; Polyethy | 2022 |
Positive interaction of mangiferin with selected oral hypoglycemic drugs: a therapeutic strategy to alleviate diabetic nephropathy in experimental rats.
Topics: Animals; Antioxidants; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Nephropathies; D | 2020 |
Gliclazide alters macrophages polarization state in diabetic atherosclerosis in vitro via blocking AGE-RAGE/TLR4-reactive oxygen species-activated NF-kβ nexus.
Topics: Animals; Antigens, Surface; Atherosclerosis; Cell Survival; Cytokines; Diabetes Complications; Diabe | 2021 |
Missed Opportunities for Deprescription: A Teachable Moment.
Topics: Aged, 80 and over; Deprescriptions; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combina | 2017 |
DEND Syndrome with Heterozygous KCNJ11 Mutation Successfully Treated with Sulfonylurea.
Topics: Base Sequence; Brain; Diabetes Mellitus; DNA; Epilepsy; Gliclazide; Glycated Hemoglobin; Heterozygot | 2017 |
Quality by Design Approach for Developing Lipid-Based Nanoformulations of Gliclazide to Improve Oral Bioavailability and Anti-Diabetic Activity.
Topics: Administration, Oral; Animals; Biological Availability; Calorimetry, Differential Scanning; Diabetes | 2019 |
Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis.
Topics: Antineoplastic Agents; Diabetes Mellitus; Gliclazide; Humans; Hypoglycemic Agents; Mutation; Phospha | 2019 |
[Effects of different sulfonylureas on the warm-up phenomenon in diabetes patients with coronary artery disease].
Topics: Angina Pectoris; Coronary Angiography; Coronary Artery Disease; Diabetes Complications; Diabetes Mel | 2017 |
Three novel mutations in MODY and its phenotype in three different Czech families.
Topics: Czechoslovakia; Diabetes Mellitus; Diet Therapy; Family Health; Gliclazide; Glucokinase; Hepatocyte | 2010 |
[Comparative characteristics of antioxidant properties of hypoglycemic agents diabenol and gliclazide].
Topics: Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus; Free Radical Scavengers; Free Radicals; Glicl | 2011 |
Diabetes mellitus and weight control: differences of respiratory quotient in type 2 diabetic obese subjects receiving sulfonylureas and non-diabetic obese controls.
Topics: Calorimetry, Indirect; Carbon Dioxide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclaz | 2003 |
Protective actions of gliclazide on high insulin-enhanced neutrophil-endothelial cell interactions through inhibition of mitogen activated protein kinase and protein kinase C pathways.
Topics: Cell Adhesion; Cells, Cultured; Diabetes Mellitus; Endothelial Cells; Endothelium, Vascular; Gliclaz | 2004 |
[The multi-level Meta analysis model combining individual level data with aggregative level data].
Topics: Data Interpretation, Statistical; Diabetes Mellitus; Gliclazide; Glycated Hemoglobin; Humans; Hypogl | 2005 |
[Rhabdomyolysis induced by fenofibrate monotherapy].
Topics: Diabetes Mellitus; Drug Interactions; Dyslipidemias; Fenofibrate; Follow-Up Studies; Gliclazide; Hum | 2006 |
Erythromelalgia in a diabetic patient managed with gabapentin.
Topics: Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Complications; Diabetes | 2008 |
Design and development of gliclazide mucoadhesive microcapsules: in vitro and in vivo evaluation.
Topics: Administration, Buccal; Animals; Capsules; Cheek; Delayed-Action Preparations; Diabetes Mellitus; Di | 2008 |
Vascular fibrinolytic activity in long term treatment with second generation sulfonylurea compounds.
Topics: alpha-Macroglobulins; Blood Vessels; Chlorpropamide; Diabetes Mellitus; Endothelium; Fibrinolysis; G | 1980 |
Pharmacokinetics of gliclazide in healthy and diabetic subjects.
Topics: Adult; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus; Gliclazide; Humans; I | 1984 |
[Long-term effect of gliclazide on platelet function in diabetes].
Topics: Blood Glucose; Blood Platelets; Cholesterol; Diabetes Mellitus; Female; Gliclazide; Humans; Insulin; | 1984 |
Measurement of gliclazide in plasma by radial compression reversed-phase liquid chromatography.
Topics: Analysis of Variance; Chromatography, High Pressure Liquid; Diabetes Mellitus; Gliclazide; Humans; P | 1984 |
Long term improvement in insulin response with gliclazide treatment.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Female; Gliclazide; Humans; Insulin; Male; | 1982 |
[Medium term effect (3 months) of hypoglycemic sulfamide treatment (gliclazide) on insulin secretion of the non-insulin dependent diabetic].
Topics: Blood Glucose; Diabetes Mellitus; Female; Gliclazide; Humans; Insulin; Male; Middle Aged; Sulfonylur | 1982 |
Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics.
Topics: Adult; Aged; Antigens; Blood Coagulation; Blood Glucose; Diabetes Mellitus; Factor VIII; Female; Gli | 1981 |
The inhibition of cancer cell stickiness, a model for investigation of platelet aggregation inhibitors in vivo. Effect of the sulfonyl urea derivatives, glibenclamide, gliclazide, and HB180, as well as the carboxylic acid derivative, meglitinide.
Topics: Animals; Benzamides; Carcinoma 256, Walker; Cell Aggregation; Diabetes Mellitus; Gliclazide; Glyburi | 1982 |
ABC of diabetes: treatment.
Topics: Diabetes Mellitus; Diabetic Nephropathies; Gliclazide; Humans; Sulfonylurea Compounds | 1982 |
[Hypoglycemic effect of diamicron in diabetic patients].
Topics: Adult; Aged; Diabetes Mellitus; Gliclazide; Humans; Middle Aged; Sulfonylurea Compounds | 1983 |
[The effect of diamicron on various blood coagulation indices in patients with type II diabetes mellitus].
Topics: Adult; Aged; Blood Coagulation; Diabetes Mellitus; Gliclazide; Humans; Middle Aged; Platelet Aggrega | 1983 |
Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus; Gliclazide; Humans; Hypoglycemic Agents; Insuli | 1980 |
[Efficacy of gliclazide in short and long-term therapy of older persons with noninsulin-dependent diabetes].
Topics: Aged; Blood Glucose; Diabetes Mellitus; Female; Gliclazide; Humans; Insulin; Male; Sulfonylurea Comp | 1981 |
The effects of gliclazide on platelet function in patients with diabetes mellitus.
Topics: Adult; Blood Platelets; Diabetes Mellitus; Female; Gliclazide; Humans; Male; Middle Aged; Platelet A | 1982 |
[Diamicron and micristin in the complex treatment of diabetes mellitus].
Topics: Adult; Aspirin; Cellulose; Crystallization; Diabetes Mellitus; Drug Therapy, Combination; Gliclazide | 1982 |
Influence of blood proteins on biomedical analysis. III. Pharmacokinetics and protein binding of gliclazide.
Topics: Adult; Blood Proteins; Diabetes Mellitus; Gliclazide; Half-Life; Humans; In Vitro Techniques; Kineti | 1981 |
[Gliclazide, a new molecule in the treatment of non-insulin-dependent diabetes mellitus].
Topics: Animals; Diabetes Mellitus; Gliclazide; Humans; Sulfonylurea Compounds | 1980 |
Reversed-phase high-performance liquid chromatographic determination of gliclazide in human plasma.
Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus; Gliclazide; Humans; Methods; Sulfonylurea C | 1980 |
[Gas-liquid chromatographic method for determination of plasma gliclazide (author's transl)].
Topics: Chromatography, Gas; Diabetes Mellitus; Gliclazide; Humans; Sulfonylurea Compounds | 1980 |
Gliclazide in the treatment of obese NIDDM patients.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Human | 1994 |
Insulin resistance in a patient with diabetes mellitus associated with Turner's syndrome.
Topics: Adult; Diabetes Complications; Diabetes Mellitus; Female; Gliclazide; Glucose Clamp Technique; Gluco | 1994 |
Gliclazide in the treatment of obese non-insulin dependent diabetic patients.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans | 1993 |
[Activity of superoxide dismutase in erythrocytes and leukocytes and levels of zinc and copper in blood of patients with diabetes. Effect of diabetic treatment on examined parameters].
Topics: Adolescent; Adult; Child; Copper; Diabetes Mellitus; Diet, Diabetic; Erythrocytes; Female; Gliclazid | 1995 |
Synthesis of putative metabolites and investigation of the metabolic fate of gliclazide, [1-(3-azabicyclo(3,3,0)oct-3-yl)-3-(4-methylphenylsulfonyl) urea], in diabetic patients.
Topics: Adult; Aged; Diabetes Mellitus; Ethnicity; Female; Gas Chromatography-Mass Spectrometry; Gliclazide; | 1996 |
Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment.
Topics: Adult; Arrhythmias, Cardiac; Diabetes Complications; Diabetes Mellitus; Digitalis Glycosides; Diuret | 1998 |
Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection.
Topics: Amputation, Surgical; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 1998 |
Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combinati | 2000 |
Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.
Topics: Anti-Infective Agents; Antifungal Agents; Diabetes Complications; Diabetes Mellitus; Drug Interactio | 2001 |
Anti-platelet effects of long-term treatment with gliclazide in diabetic patients.
Topics: Adenosine Diphosphate; Bleeding Time; Blood Glucose; Blood Platelets; Diabetes Mellitus; Gliclazide; | 1979 |
[Effects of the prolonged use of gliclazide in diabetic black Africans (apropos of 51 cases in Dakar)].
Topics: Adult; Aged; Black People; Diabetes Mellitus; Female; Gliclazide; Humans; Male; Middle Aged; Senegal | 1979 |
[Therapeutic value of a new hypoglycemic agent (gliclazide) in the treatment of diabetes mellitus].
Topics: Adult; Aged; Diabetes Mellitus; Drug Evaluation; Female; Gliclazide; Humans; Male; Middle Aged; Sulf | 1978 |
[Therapeutic value of a new oral antidiabetic agent: gliclazide].
Topics: Adult; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus; Drug Evaluation; Drug | 1978 |
[Early results of the treatment of diabetes with a (methyl-4-phenylsulfonyl)-1-[perhydrocyclopenta(C)pyrrolyl-2]-3-urea (gliclazide)
Topics: Adult; Aged; Diabetes Mellitus; Drug Evaluation; Female; Gliclazide; Humans; Male; Middle Aged; Sulf | 1978 |
[Hypoglycemic complications of oral drug therapy of diabetes mellitus. 21 cases].
Topics: Age Factors; Aged; Diabetes Mellitus; Diabetic Coma; Drug Interactions; Female; Gliclazide; Glyburid | 1976 |
[Significance of an oral antidiabetic with vascular action: gliclazide in the asymptomatic diabetes and patent diabetes].
Topics: Adult; Diabetes Mellitus; Female; Gliclazide; Humans; Male; Middle Aged; Prediabetic State; Sulfonyl | 1976 |
International Symposium on Diabetes, Vascular Risks, and Gliclazide (Diamicron). Washington, DC, June 28, 1991.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Gliclazide; Humans | 1992 |
Influence of blood proteins on biomedical analysis. XII. Effects of glycation on gliclazide (oral hypoglycemic drug)-binding with serum albumin in diabetics.
Topics: Blood Proteins; Diabetes Mellitus; Gliclazide; Humans; Kinetics; Protein Binding; Serum Albumin | 1992 |
Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazid | 1991 |
The gliclazide poster world in Lisbon, 1989.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Gliclazide; Humans; Tissue Plasminogen Activator | 1991 |
[New oral antidiabetic agents].
Topics: Animals; Cyclohexanols; Diabetes Mellitus; Drug Evaluation; Gliclazide; Glyburide; Humans; Hypoglyce | 1990 |
Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Erythrocytes; Female; Gliclazide; | 1985 |